These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25528496)

  • 1. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma.
    Matulonis U; Vergote I; Backes F; Martin LP; McMeekin S; Birrer M; Campana F; Xu Y; Egile C; Ghamande S
    Gynecol Oncol; 2015 Feb; 136(2):246-53. PubMed ID: 25528496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Dose-Escalation Study of Pilaralisib (SAR245408, XL147) in Combination with Paclitaxel and Carboplatin in Patients with Solid Tumors.
    Wheler J; Mutch D; Lager J; Castell C; Liu L; Jiang J; Traynor AM
    Oncologist; 2017 Apr; 22(4):377-e37. PubMed ID: 28275119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
    Edelman G; Rodon J; Lager J; Castell C; Jiang J; Van Allen EM; Wagle N; Lindeman NI; Sholl LM; Shapiro GI
    Oncologist; 2018 Apr; 23(4):401-e38. PubMed ID: 29593099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.
    Blackwell K; Burris H; Gomez P; Lynn Henry N; Isakoff S; Campana F; Gao L; Jiang J; Macé S; Tolaney SM
    Breast Cancer Res Treat; 2015 Nov; 154(2):287-97. PubMed ID: 26497877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors.
    Soria JC; LoRusso P; Bahleda R; Lager J; Liu L; Jiang J; Martini JF; Macé S; Burris H
    Oncologist; 2015 Mar; 20(3):245-6. PubMed ID: 25669662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma.
    Bechter OE; Dumez H; Costermans J; Punie K; Hsu K; Dedieu JF; Ghuysen AF; Francesconi E; Sharma J; Liu L; Schöffski P
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):83-90. PubMed ID: 27169794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.
    Tolaney S; Burris H; Gartner E; Mayer IA; Saura C; Maurer M; Ciruelos E; Garcia AA; Campana F; Wu B; Xu Y; Jiang J; Winer E; Krop I
    Breast Cancer Res Treat; 2015 Jan; 149(1):151-61. PubMed ID: 25537644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
    Heudel PE; Fabbro M; Roemer-Becuwe C; Kaminsky MC; Arnaud A; Joly F; Roche-Forestier S; Meunier J; Foa C; You B; Priou F; Tazi Y; Floquet A; Selle F; Berton-Rigaud D; Lesoin A; Kalbacher E; Lortholary A; Favier L; Treilleux I; Ray-Coquard I
    Br J Cancer; 2017 Jan; 116(3):303-309. PubMed ID: 28072765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors.
    Shapiro GI; Rodon J; Bedell C; Kwak EL; Baselga J; Braña I; Pandya SS; Scheffold C; Laird AD; Nguyen LT; Xu Y; Egile C; Edelman G
    Clin Cancer Res; 2014 Jan; 20(1):233-45. PubMed ID: 24166903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.
    Brown JR; Davids MS; Rodon J; Abrisqueta P; Kasar SN; Lager J; Jiang J; Egile C; Awan FT
    Clin Cancer Res; 2015 Jul; 21(14):3160-9. PubMed ID: 25840972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer.
    Del Campo JM; Birrer M; Davis C; Fujiwara K; Gollerkeri A; Gore M; Houk B; Lau S; Poveda A; González-Martín A; Muller C; Muro K; Pierce K; Suzuki M; Vermette J; Oza A
    Gynecol Oncol; 2016 Jul; 142(1):62-69. PubMed ID: 27103175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
    Arend RC; Davis AM; Chimiczewski P; O'Malley DM; Provencher D; Vergote I; Ghamande S; Birrer MJ
    Gynecol Oncol; 2020 Feb; 156(2):301-307. PubMed ID: 31870556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line lenvatinib in patients with recurrent endometrial cancer.
    Vergote I; Powell MA; Teneriello MG; Miller DS; Garcia AA; Mikheeva ON; Bidzinski M; Cebotaru CL; Dutcus CE; Ren M; Kadowaki T; Funahashi Y; Penson RT
    Gynecol Oncol; 2020 Mar; 156(3):575-582. PubMed ID: 31955859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.
    Nishio S; Shimokawa M; Tasaki K; Nasu H; Yoshimitsu T; Matsukuma K; Terada A; Tsuda N; Kawano K; Ushijima K
    Gynecol Oncol; 2018 Sep; 150(3):432-437. PubMed ID: 30037491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
    Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
    Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia.
    Castonguay V; Lheureux S; Welch S; Mackay HJ; Hirte H; Fleming G; Morgan R; Wang L; Blattler C; Ivy PS; Oza AM
    Gynecol Oncol; 2014 Aug; 134(2):274-80. PubMed ID: 24882554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.
    Papadopoulos KP; Tabernero J; Markman B; Patnaik A; Tolcher AW; Baselga J; Shi W; Egile C; Ruiz-Soto R; Laird AD; Miles D; Lorusso PM
    Clin Cancer Res; 2014 May; 20(9):2445-56. PubMed ID: 24583798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and toxicity predictors of response and progression to temsirolimus in women with recurrent or metastatic endometrial cancer.
    Goodwin RA; Jamal R; Tu D; Walsh W; Dancey J; Oza AM; Elit L; Eisenhauer EA
    Gynecol Oncol; 2013 Nov; 131(2):315-20. PubMed ID: 23938374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.
    McMeekin DS; Lisyanskaya A; Crispens M; Oza AM; Braly P; Doering D; Bayever E; Michiels B; Markman M
    Gynecol Oncol; 2009 Aug; 114(2):288-92. PubMed ID: 19476988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.
    Tsoref D; Welch S; Lau S; Biagi J; Tonkin K; Martin LA; Ellard S; Ghatage P; Elit L; Mackay HJ; Allo G; Tsao MS; Kamel-Reid S; Eisenhauer EA; Oza AM
    Gynecol Oncol; 2014 Nov; 135(2):184-9. PubMed ID: 25173583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.